European Journal of Chemistry

Effect of inclusion of citric acid and Lutrol® F-68 on ziprasidone and β-cyclodextrin complexation: Characterization, solubility and dissolution studies


Main Article Content

Vaishali Yogesh Londhe
Sreevidya Ramesh Krishnan


Ziprasidone (ZPR) is an antipsychotic agent having less solubility. It is used for the treatment of schizophrenia. Complexation of hydrophobic drugs with cyclodextrins leads to enhanced solubility and dissolution. In this study, inclusion complexes were prepared by different methods, using ZPR, β-cyclodextrin (β-CD), and different auxiliary agents like hydrophilic polymer and hydroxy acid (1:1:0.5) to improve the aqueous solubility. The characterization of the ternary complexes was carried out using solubility study, Differential scanning calorimetry (DSC), Powder X-ray diffraction (PXRD), Fourier transformation infrared spectroscopy (FT-IR) and in vitro dissolution studies. DSC, XRD, and FT-IR studies showed interaction in drug, cyclodextrin, and auxiliary agents which are confirmed by enhancement of solubility and dissolution. Spray-dried dispersion showed less crystallinity and higher solubility as compared to the kneading method for both citric acid and Lutrol® F-68. Thus, the investigation concludes that the presence of the auxiliary agent has a synergistic action on complexation with cyclodextrin, which helps to modify the physicochemical properties of the drug.

icon graph This Abstract was viewed 1270 times | icon graph Article PDF downloaded 496 times

How to Cite
Londhe, V. Y.; Krishnan, S. R. Effect of Inclusion of Citric Acid and Lutrol® F-68 on Ziprasidone and β-Cyclodextrin Complexation: Characterization, Solubility and Dissolution Studies. Eur. J. Chem. 2020, 11, 280-284.

Article Details

Crossref - Scopus - Google - European PMC

[1]. Gribbon, P.; Andreas, S. Drug Discov. Today 2005, 1, 17-22.

[2]. Kim, C. K.; Park, J. S. Am. J. Drug Deliv. 2004, 2, 113-130.

[3]. Leuner, C.; Dressman, J. Eur. J. Pharm. Biopharm. 2000, 50, 47-60.

[4]. Brewster, M. E.; Loftsson, T. Adva. Drug Deliv. Rev. 2007, 59, 645-666.

[5]. Loftsson, T.; Duchene, D. Inter. J. Pharm. 2007, 329, 1-11.

[6]. Conceicao, J.; Adeoye, O.; Cabral-Marques, H. M.; Lobo, J. Curr. Pharm. Design 2018, 24, 1405-1433.

[7]. Sherje, A.; Londhe, V. Curr. Drug Discov. Tech. 2014, 11, 271-278.

[8]. Sigurdardottir, A. M.; Loftsson, T. Int. J. Pharm. 1995, 126, 73-78.

[9]. Danel, C.; Azaroual, N.; Chavaria, C.; Odou, V.; Martel, B.; Vaccher, C. Carbohydr. Polym. 2013, 92, 2282-2292.

[10]. Gaspar de Araujo, M. V. J. Mol. Struc. 2017, 1150, 146-154.

[11]. Patel, P.; Agrawal, Y. K.; Sarvaiya, J. Int. J. Bio. Macromol. 2016, 84, 182-188.

[12]. Soliman, K. A.; Ibrahim, H. K.; Ghorab, M. M. Int. J. Pharm. 2016, 512, 168-177.

[13]. Pokharkar, V.; Khanna, A.; Venkatpurwar, V.; Dhar, S.; Mandpe, L. Acta Pharm. 2009, 59, 121-132.

[14]. Redenti, E.; Szente, L.; Szejtli, J. J. Pharm. Sci. 2000, 89, 1-8.<1::AID-JPS1>3.0.CO;2-W

[15]. Sherje, A. P.; Londhe, V. J. Pharm. Innov. 2015, 10, 324-334.

[16]. Taupitz, T.; Dressman, J. B.; Buchanan, C. M.; Klein, S. Eur. J. Pharm. Biopharm. 2013, 83, 378-387.

[17]. Rakkaew, P.; Suksiriworapong, J.; Chantasart, D. Pharm. Dev. Technol. 2018, 23, 715-722.

[18]. Germain, P.; Bilial, M.; De Brauner, C. Termochim. Acta 1995, 259, 187-198.

[19]. Fenyvesi, E.; Vikmon, M.; Szema, J.; Redenti, E.; Del-canale, M.; Ventura, P.; Szejtli, J. J. Incl. Phenom. 1999, 33, 339-344.

[20]. Haque, N.; Prabhu, N. P. Biochem. Biophys. Res. Commun. 2018, 499, 907-912.

[21]. Li, X.; Yang, M.; Li, Y.; Gong, W.; Wang, Y.; Shan, L.; Shao, S.; Gao, C. Current Drug Deliv. 2017, 14, 1130-1143.

[22]. Daniel, D. G.; Zimbroff, D. L.; Potkin, S. G.; Reeves, K. R.; Harrigan, E. P.; Lakshmi Narayanan, M. Neuropsychopharmacology 1999, 20, 491-505.

[23]. Gauniya, A.; Mazumder, R.; Pathak, K. Int. J. Pharm. Pharm. Sci. 2015, 7, 146-150.

[24]. Thombre, A. G.; Shah, J. C.; Sagawa, K.; Caldwell, W. B. Int. J. Pharm. 2012, 428, 8-17.

[25]. Mogal, P.; Derle, D. J. Drug Design Med. Chem. 2017, 3, 37-48.

[26]. Kim, Y.; Oksanen, A. D.; Massefski, W.; Blake, F. J. Jr.; Duffy, M. E.; Chrunyk, B. J. Pharm. Sci. 1998, 87, 1560-1567.

[27]. Thombre, A. G.; Herbig, S. M.; Alderman, J. A. Pharm. Res. 2011, 28, 3159-3170.

[28]. Deshmukh, S. S.; Potnis, V. V.; Shelar, D. B.; Mahaparale, P. Indian Drugs 2007, 44, 677-682.

[29]. Miao, Y.; Chen, G.; Ren, L.; Pingkai, O. Drug Deliv. 2016, 23, 2163-2172.

[30]. Higuchi, T. K. A. C. Adv. Anal. Chem. Instrum. 1965, 4, 117-211.

[31]. Londhe, V. Y.; Deshmane, A. B.; Singh, S. R.; Kulkarni, Y. A. J. Mol. Struc. 2018, 1157, 395-400.

[32]. Dua, K.; Pubreja K.; Ramana, M. V.; Lather, V. J. Pharm. Bioallied Sci. 2011, 3(3), 417-425.

[33]. National Library of Medicine, PubChem, Retrieved Mar 22, 2019, from https://pubchem. ncbi. nlm. nih. gov/compound/Ziprasidone

[34]. Londhe, V. Y.; Pawar A.; Kundaikar, H. J. Mol. Struc. 2020, 1220, 128615.

Supporting Agencies

Most read articles by the same author(s)

Dimensions - Altmetric - scite_ - PlumX

Downloads and views


Download data is not yet available.


Metrics Loading ...
License Terms

License Terms


Copyright © 2024 by Authors. This work is published and licensed by Atlanta Publishing House LLC, Atlanta, GA, USA. The full terms of this license are available at and incorporate the Creative Commons Attribution-Non Commercial (CC BY NC) (International, v4.0) License ( By accessing the work, you hereby accept the Terms. This is an open access article distributed under the terms and conditions of the CC BY NC License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited without any further permission from Atlanta Publishing House LLC (European Journal of Chemistry). No use, distribution, or reproduction is permitted which does not comply with these terms. Permissions for commercial use of this work beyond the scope of the License ( are administered by Atlanta Publishing House LLC (European Journal of Chemistry).